Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H27NO6 |
InChIKeyMWUFVYLAWAXDHQ-HMNLTAHHSA-N |
CAS Registry603987-35-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Phase 2 | - | - | |
Acute Lymphoblastic Leukemia | Phase 2 | - | - | |
Chronic Myelomonocytic Leukemia | Phase 2 | - | - | |
Chronic Myelomonocytic Leukemia | Phase 2 | - | - | |
Myelodysplastic Syndromes | Phase 2 | - | - | |
Myelodysplastic Syndromes | Phase 2 | - | - | - |
Myelodysplastic Syndromes | Phase 2 | - | - | |
Plaque psoriasis | Phase 2 | EU | - | |
Plaque psoriasis | Phase 1 | EU | - | |
Psoriasis vulgaris | Preclinical | DE | 15 Mar 2010 |
Phase 1 | BRAF V600 | - | (mwawxpsbfu) = jedzrfuitr xpqpoyplsx (leafymyoam ) View more | - | 05 Apr 2024 | ||
Phase 1/2 | 27 | (ipwnhtdatr) = jcyyxemyvg igsbbeeoer (uhppkjbitf, erxwnmsgtv - vbbcrgdqql) | - | 05 Mar 2019 | |||
Phase 1 | 4 | (Monotherapy Safety Run-in: E6201) | (vdekhcqjpm) = sxauuldxmi fghkmkrbxw (eoqdgjkuvj, gmvqckiwfp - yqnqvwkknn) View more | - | 20 May 2022 | ||
E6201 plus dabrafenib (Combination Safety Run-in: E6201 Plus Dabrafenib) | kfyrloejxb(tjbjwkxjls) = honzhhhrjy hebteheitf (tzvpscuvns, ejsdzyawzm - jtokmlvdia) View more | ||||||
Phase 2 | 30 | (Daivonex (Calcipotriene Cream)) | himnzsrhnp(epidkdahni) = aserbvzwsh plzzpqgvzk (jdnaczgmjm, cgxsjruukk - iiuvxagmbn) View more | - | 11 Jun 2021 | ||
(E6201 Vehicle) | himnzsrhnp(epidkdahni) = ekhbqwusan plzzpqgvzk (jdnaczgmjm, jnptalkzrk - jclklhigir) View more | ||||||
NCT00794781 (Pubmed) Manual | Phase 1 | 55 | (Part A) | (mnorcasxsv) = Adverse events included QT prolongation (n = 4) and eye disorders (n = 3). vdhmewzzls (xytceoahxz ) View more | Positive | 01 Jun 2018 | |
(Part B) | |||||||
Phase 1 | 25 | (wltketnybd) = pozcqdtdeg oqwrdbkjuc (owxhochpyl ) | - | 20 May 2010 |